BRAF and colorectal carcinoma: Moreover, BRAF mutations often co-occur with MSI status in CRC and, according to the consensus molecular subtype (CMS) classification, define the MSI-immune CMS1 subtype, which is characterized by pronounced immune cell infiltration and activation [17].